Merck & Co., Inc. (MRK)
- Sector
- Health Care
- Industry
- Pharmaceuticals
- Last price
- $147.37
- As of
Kresmion compiles this page from MRK's SEC filings, its 13F institutional holders and the market events Kresmion detects, each linked to its source.
Merck & Co., Inc. (MRK): 6 institutional managers tracked by Kresmion reported non-option positions in their 2026Q2 Form 13F filings, and the most recent SEC filing on record for the company is a Form 8-K filed 2026-10-13.
See the full MRK dossier
Price with insider and filing markers, who is positioning, fundamentals and peers for MRK on one page. Preview it with sample data, then open it live with a free account.
Preview the MRK dossierActive signals for MRK
- highCONSENSUS_SELL
3 tracked funds reduced MRK this 2026Q2, institutional consensus
- highINSTITUTIONAL_EXIT
CITADEL ADVISORS LLC cut 50% of MRK (2026Q2)
- highINSTITUTIONAL_SURGE
Point72 Asset Management, L.P. added +453% to MRK (2026Q2)
- highINSTITUTIONAL_EXIT
MILLENNIUM MANAGEMENT LLC cut 83% of MRK (2026Q2)
- highINSTITUTIONAL_EXIT
MILLENNIUM MANAGEMENT LLC cut 72% of MRK (2026Q2)
FREE, NO ACCOUNT
Every signal on MRK, as it fires
You are seeing 5 of 139 signals recorded on MRK since 2026-05-02.
The five above landed across 2 days. The other 134 were recorded on 31 other days.
No fixed schedule: it goes out when the data has something in it. Unsubscribe anytime. We never sell your data.
Largest reported share positions in MRK (2026Q2)
| Manager / security | Market value | % portfolio | QoQ |
|---|---|---|---|
| D. E. Shaw & Co., Inc.CUSIP 58933Y105 · 2026Q2 | $351.8M | 0.17% | , |
| CITADEL ADVISORS LLCCUSIP 58933Y105 · 2026Q2 | $248.5M | 0.03% | , |
| MILLENNIUM MANAGEMENT LLCCUSIP 58933Y105 · 2026Q2 | $72.1M | 0.03% | , |
| Point72 Asset Management, L.P.CUSIP 58933Y105 · 2026Q2 | $48.8M | 0.05% | , |
| TWO SIGMA INVESTMENTS, LPCUSIP 58933Y105 · 2026Q2 | $6.2M | 0.00% | , |
| Bridgewater Associates, LPCUSIP 58933Y105 · 2026Q2 | $3.9M | 0.02% | , |
Quarterly SEC Form 13F disclosures from the managers Kresmion tracks, not a complete ownership ranking. Non-option holdings only; reported put and call positions are excluded. Different securities are labeled by CUSIP. Values are reporting-period snapshots, not current position values. Filings can arrive up to 45 days after quarter-end.
Recent SEC filings, MRK
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
MRK against its peers
MRK's net margin of 28.1% ranks in the 80th percentile of 22 Pharmaceuticals sub-industry peers, fiscal periods ending between 2025-12-28 and 2025-12-31.
| Metric | MRK | Peer median | Percentile | n |
|---|---|---|---|---|
| Revenue FY | 65.0B USD | 6.2B USD | 89 | 21 |
| Gross margin | n/a | 70.1% | n/a | 10 |
| Operating margin | n/a | 10.5% | n/a | 16 |
| Net margin | 28.1% | 10.3% | 80 | 22 |
| Return on equity | 34.7% | 15.4% | 77 | 23 |
| P / E | 20.2x | 21.5x | 46 | 11 |
| 1 year | 74.0% | 28.7% | 82 | 24 |
Peers (25): NVS, AZN, JNJ, NVO, PFE, LLY, BMY, GSK, TEVA, ZTS, VTRS, JAZZ, CORT, AXSM, AMRX, OGN, AMLX, TARS, SUPN, LQDA, BHC, HRMY, XERS, TRVI, GPCR. Fiscal periods ending between 2025-12-28 and 2025-12-31. Every figure is one full fiscal year read from one annual filing (MRK: 10-K), reported in USD. Nothing is trailing twelve months and nothing is converted between currencies. Source: SEC EDGAR XBRL company facts (public domain); prices from Kresmion's daily equity market-data snapshot. Open the full comparison.
Related tickers
Follow MRK on a live board
Kresmion is a cross-asset market-intelligence terminal. Open a board scoped to MRK for its filings, 13F changes, insider trades, options positioning, and confluence read in one view, each with its source.